During an episode of her talk-show, Farah Khan reveals an Hilarious yet embarrassing moment when she slipped and fell after ...

What are these electric blue ponds in the middle of the Utah desert? And why do they keep changing color? Join Derek Muller as he looks into the weird, bizarre, and seemingly inexplicable images found ...

Join us for Day 3 on the opulent $1 billion Sun Princess as we embark on an unforgettable adventure in Roatan, Honduras! Dive ...

Vanderpump Rules alum Lala Kent thanked the rescue dog she adopted 14 years ago for seeing her through life's biggest moments ...

Anastasia Karanikolaou just turned up the heat on Instagram in her latest post. She posted pictures of herself looking absolutely stunning in a black top with a deep neck. Famously known for being ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons it didn’t disclose. Lilly closed the trial on ...

Eli Lilly has pulled the plug on a phase 2b obesity trial before enrolling a single patient, citing “strategic business reasons.” The study was designed to test bimagrumab, an asset Lilly acquired in ...

Indianapolis-based pharmaceutical giant Eli Lilly confirms plans to build a $5 billion manufacturing facility just west of Richmond, Virginia. (Courtesy Eli Lilly) Indianapolis-based pharmaceutical ...

Lilly's orforglipron shows superior weight loss and blood sugar control Highest dose of the pill leads to 9.2% weight reduction Detailed trial results to be presented at future medical meeting The ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. An investigational GLP-1 ...

Patients on Eli Lilly & Co.’s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk A/S in the first head-to-head ...